Hexarelin

Hexarelin, also known as examorelin, is a synthetic six-amino-acid peptide belonging to the family of growth hormone-releasing peptides (GHRPs). Its sequence, His-D-2-methyl-Trp-Ala-Trp-D-Phe-Lys-NH₂, is a close structural relative of GHRP-6, from which it was derived by substituting a methylated D-tryptophan in position two. That single modification makes the molecule more resistant to enzymatic breakdown than its parent compound, which is the usual reason D-amino acids and C-terminal amides are built into peptides of this class.

The GHRP story begins well before hexarelin itself. In the late 1970s and 1980s, researchers observed that certain opioid-derived peptide fragments released growth hormone through a pathway that did not involve the known growth hormone-releasing hormone (GHRH) receptor. Successive rounds of medicinal chemistry produced GHRP-6, then more potent analogues including GHRP-2 and hexarelin. Hexarelin was investigated during the 1990s mainly as a pharmacological probe and candidate diagnostic agent: because it provokes a large, reproducible growth hormone surge, it was tested as a way of assessing pituitary growth hormone reserve.

It is important to state the end of that story clearly. Hexarelin never completed the development path to approval. No regulatory agency has authorised it as a medicine for any indication, there are no large randomised trials of clinical endpoints, and the molecule circulates today almost entirely as a research chemical sold for laboratory use. Anything written about it, including this guide, describes a research compound and not a therapy.

This guide covers what the peer-reviewed literature reports: how hexarelin engages its receptors, what was measured in the human studies that exist, how the growth hormone response behaves on repeated exposure, why a second receptor (CD36) brought cardiac researchers into the field, and how hexarelin sits next to related peptides such as GHRP-2, GHRP-6 and ipamorelin. Practical questions about preparing a vial are handled separately on the hexarelin tool page and are deliberately outside the scope of this article.

Hexarelin is an agonist at the growth hormone secretagogue receptor type 1a (GHS-R1a). This receptor was cloned and characterised by a Merck group and reported in Science in 1996, which established that the synthetic secretagogues acted through a G protein-coupled receptor expressed in the pituitary and the hypothalamus, distinct from the GHRH receptor (Howard et al., 1996). Three years later, ghrelin was identified as the endogenous ligand of that same receptor, which reframed every GHRP as a synthetic ghrelin mimetic rather than an orphan drug in search of a target.

Mechanistically, GHS-R1a couples mainly to the Gq pathway. Receptor activation stimulates phospholipase C, generates inositol trisphosphate, and raises intracellular calcium in somatotroph cells, which triggers the release of stored growth hormone. The calcium signal is fast and measurable in vitro within minutes, a detail that becomes relevant to the desensitization question discussed below (Orkin et al., 2003).

Because hexarelin and GHRH act through two different receptors and two different intracellular routes, their effects are not redundant. GHRH works largely through cyclic AMP, while hexarelin works through the calcium pathway, and a component of the GHRP effect also involves the hypothalamus, where these peptides appear to blunt somatostatin tone and to recruit GHRH-producing neurons. That is the pharmacological basis for the observation, reported repeatedly in the 1990s literature, that a GHRP produces a larger growth hormone response than GHRH alone and that combining the two produces more than either.

GHS-R1a is not confined to the pituitary. The receptor is also found in the hypothalamic nuclei that govern appetite, and in various peripheral tissues, which is why GHRPs are studied for effects on food intake, gastric motility and metabolism as well as growth hormone. Hexarelin, however, has a second and unrelated binding partner, CD36, and that duality is what makes its pharmacology more complicated than that of a straightforward growth hormone secretagogue.

This section describes receptor biology observed in laboratory and animal systems. It does not imply any clinical benefit in humans.

The honest summary is that hexarelin was studied in humans in small, short, hormone-focused protocols, mostly between 1994 and 2002, and that no study of clinical outcomes such as body composition over years, fracture risk, cardiovascular events or mortality was ever published.

The pharmacodynamic shape of the response was mapped in a dose-response study in healthy adult men published in the Journal of Clinical Endocrinology and Metabolism in 1996. Intravenous hexarelin produced a graded growth hormone rise that reached a plateau, and the authors also recorded parallel rises in prolactin and cortisol, establishing from the start that the hormonal effect was not confined to growth hormone (Massoud et al., 1996).

A comparative study published in Peptides in 1997 examined six normal young adults aged 22 to 27 and compared hexarelin with GHRP-2, GHRH, thyrotropin-releasing hormone and human corticotropin-releasing hormone. Hexarelin and GHRP-2 produced similar and strong growth hormone responses, larger than the response to GHRH, together with slight stimulatory effects on prolactin, ACTH and cortisol (Arvat et al., 1997).

Repeated subcutaneous administration was studied in six normal young men by a Turin and Mayo Clinic collaboration published in the European Journal of Endocrinology in 2002. Using deconvolution analysis of 24-hour profiles, the authors found that intermittent daily injections amplified 24-hour growth hormone secretion by selectively increasing the mass of growth hormone secretory pulses, without altering lactotroph or corticotroph secretion across the day (Maccario et al., 2002). In other words, the acute bolus effect on prolactin and cortisol did not necessarily translate into a sustained shift of those axes under an intermittent schedule.

Hexarelin was also given to patient groups rather than only to healthy volunteers, including adults with hypopituitarism and growth hormone deficiency, and to elderly volunteers in the longest published protocol. Those studies are discussed in the sections on desensitization and cardiac effects. Across the whole human literature, sample sizes in the single digits to low teens are the norm, which is adequate for describing a hormone curve and inadequate for establishing safety or efficacy.

This is the most consistently replicated limitation of hexarelin, and it is the finding that most often gets lost when the peptide is discussed outside the scientific literature.

The pivotal observation comes from a group at the Christie Hospital in Manchester. Twelve healthy elderly volunteers received twice-daily subcutaneous hexarelin for 16 weeks, and the growth hormone response to a test injection was measured at baseline and during the study. The mean area under the growth hormone curve was 19.1 at week 0, 13.1 at week 1, 12.3 at week 4 and 10.5 microg/l per hour at week 16, with the decreases at weeks 4 and 16 reaching statistical significance against baseline (Rahim et al., 1998). The growth hormone axis, in short, became progressively less responsive to the same stimulus.

The same work supplies the reassuring half of the picture. Four weeks after the 16-week period ended, hexarelin was administered again and the area under the growth hormone curve rose significantly compared with week 16, returning to a value that was no longer statistically different from baseline. The attenuation was therefore reversible after a washout rather than a permanent exhaustion of the somatotroph population.

In vitro work provides a plausible receptor-level explanation. In cells expressing the growth hormone secretagogue receptor, the calcium response to hexarelin desensitised markedly within minutes of a first exposure, consistent with the rapid uncoupling and internalisation typical of G protein-coupled receptors under sustained agonist pressure (Orkin et al., 2003). A review of the question published in Growth Hormone and IGF Research framed the same conclusion from the clinical side: desensitization to hexarelin does occur.

Two caveats are worth keeping. First, desensitization is schedule-dependent: studies using short-term or intermittent administration, including intranasal and oral protocols in elderly subjects, did not always detect a loss of responsiveness. Second, desensitization at GHS-R1a does not necessarily close the GHRH pathway, which is a separate receptor system. None of this translates into guidance on how to use the compound, and nothing in this article should be read that way.

In the late 1990s, researchers noticed that GHRPs produced cardiovascular effects that did not track with growth hormone levels, including effects in animals whose pituitary had been removed. The explanation turned out to be a second, structurally unrelated binding site.

A study published in Circulation Research in 2002 identified CD36, a multifunctional scavenger receptor and long-chain fatty acid transporter, as a cardiac binding partner for hexarelin. CD36 was shown to be expressed in cardiomyocytes and in microvascular endothelial cells, and activation of CD36 by hexarelin in perfused hearts produced a dose-dependent increase in coronary perfusion pressure (Bodart et al., 2002). Later photoaffinity cross-linking work localised the hexarelin binding region within the CD36 sequence. Hexarelin therefore has two distinct pharmacologies: a growth hormone pharmacology mediated by GHS-R1a, and a cardiovascular pharmacology in which both GHS-R1a and CD36 participate.

Human cardiac data exist, but they are minimal. Seven adult men with growth hormone deficiency, plus control subjects, were studied by equilibrium radionuclide angiocardiography after intravenous hexarelin. Left ventricular ejection fraction increased in both groups, while catecholamine levels, blood pressure and cardiac output were unchanged. The authors described a short-lasting positive inotropic effect that was probably independent of growth hormone and mediated by myocardial receptors for growth hormone secretagogues (Bisi et al., 1999). A single acute imaging study in seven patients is a mechanistic signal, not evidence of therapeutic benefit.

The remainder of the cardiac literature is preclinical. In rodent models, hexarelin has been reported to limit injury after ischaemia and reperfusion, with improved cardiac systolic function, lower malondialdehyde production as a marker of oxidative stress, and a greater number of surviving cardiomyocytes, with interleukin-1 signalling implicated as a pathway (Huang et al., 2017). Other rodent and cell studies have examined effects on cardiac fibroblast proliferation, collagen synthesis and hypertrophy signalling.

The gap between these findings and clinical practice is wide. Rodent infarct models have historically failed to predict benefit in human cardiovascular trials, and there is no completed outcome trial of hexarelin in heart disease. Nothing here supports the use of hexarelin for any cardiac condition. Anyone with a cardiac diagnosis should be discussing evidence-based, approved treatments with a cardiologist.

The first-generation GHRPs are not selective for growth hormone, and hexarelin is no exception. This matters because prolactin and the hypothalamic-pituitary-adrenal axis have their own physiology, and stimulating them is not a neutral side effect.

Acute intravenous administration is the condition under which the non-selectivity is most visible. The 1996 dose-response work in healthy men documented prolactin and cortisol rises alongside the growth hormone rise (Massoud et al., 1996), and the 1997 comparative study in six young adults recorded slight but real stimulatory effects on prolactin, ACTH and cortisol for both hexarelin and GHRP-2 (Arvat et al., 1997). Separate work showed that these responses vary with age, with different patterns in prepubertal children, pubertal children, young adults and elderly subjects. Investigations into the mechanism have implicated arginine vasopressin in the activation of the adrenal axis, which places part of the effect above the pituitary rather than within it.

Chronic intermittent subcutaneous administration looks different. In the 16-week Manchester protocol, the ACTH, cortisol and prolactin responses to the morning injection were assessed, and the authors concluded that over-stimulation of the pituitary-adrenal axis and of prolactin secretion did not occur under that regimen (Rahim et al., 1999). The 24-hour deconvolution study reached a compatible conclusion: repeated daily subcutaneous injections amplified growth hormone pulse mass without altering lactotroph and corticotroph secretion, even though an intravenous bolus given at the end of the profile still raised growth hormone, prolactin, ACTH and cortisol (Maccario et al., 2002).

The practical reading is nuanced rather than reassuring. The route and pattern of exposure appear to determine whether the prolactin and cortisol effects are a transient spike or a sustained shift, and the studies that found no sustained shift involved six to twelve people over weeks to months. Sustained elevation of cortisol has well-documented consequences for glucose metabolism, bone and immune function, and elevated prolactin can disturb reproductive hormones. Those risks have not been excluded for hexarelin; they have simply not been adequately studied.

All four peptides are GHS-R1a agonists, so they share a mechanism and differ in potency, selectivity and the amount of evidence behind them. The table below summarises what the literature supports, with no quantities of any kind.

The selectivity contrast is the single most useful distinction. Hexarelin and GHRP-6 recruit the adrenal axis and the lactotrophs to a measurable degree; ipamorelin was specifically selected in preclinical screening not to. That difference is why ipamorelin dominates contemporary discussion of this class while hexarelin remains largely a historical and mechanistic subject, despite hexarelin's potency.

A second distinction concerns the type of peptide involved. GHRPs act at GHS-R1a, whereas sermorelin and CJC-1295 are GHRH analogues acting at a different receptor. Readers comparing the two families may find the discussion in sermorelin versus ipamorelin useful, since the receptor difference, not marketing positioning, explains most of the divergence in their hormone profiles.

None of these four peptides is an approved medicine for growth hormone deficiency or for any performance or anti-aging indication. Comparing them is an exercise in pharmacology, not a ranking of treatments.

Hexarelin has no marketing authorisation anywhere. It has not been approved by the United States Food and Drug Administration, by the European Medicines Agency or by comparable national agencies for any indication. Its development stalled after the exploratory clinical work of the 1990s, and the compound is now supplied as a chemical labelled for research use only.

In sport, the position is unambiguous. Growth hormone secretagogues and growth hormone-releasing peptides are listed in section S2 of the World Anti-Doping Agency Prohibited List, which applies at all times, both in competition and out of competition. Hexarelin is named explicitly in that section under its alternative name examorelin, alongside GHRP-1 through GHRP-6. Athletes in any WADA-compliant sport should treat exposure to hexarelin as an anti-doping rule violation with the full consequences that follow.

National law varies considerably and changes. In some jurisdictions the sale of unapproved peptides for human consumption is an offence, in others the compound sits in a grey zone as a laboratory reagent, and in several countries importing it for personal use can be treated as importing an unapproved medicinal product. Readers should check the rules that apply where they live rather than assume that availability online implies legality.

Product quality is a separate practical concern. Because research-grade material is outside pharmaceutical oversight, there is no regulator verifying identity, purity, endotoxin content or sterility, and analytical surveys of the broader research peptide market have repeatedly found mislabelled and underdosed vials. Questions about how a vial is prepared are handled on the hexarelin tool page and are intentionally not discussed here.

Medical disclaimer: this article is for educational purposes only. It is not medical advice, it recommends no amount, schedule or route of administration, and it does not encourage use of an unapproved substance. Anyone considering any intervention affecting the growth hormone axis should consult a qualified healthcare professional, and anyone with a suspected growth hormone disorder should be evaluated with approved diagnostic tests.

The published human experience with hexarelin is too small to support a meaningful safety profile, and that absence of data is itself the most important safety statement that can be made. What follows is what the literature records, not a complete list of what could occur.

In the acute human studies, the dominant reported effects were hormonal rather than symptomatic. Several protocols noted that administration was tolerated without reported adverse events in the volunteers studied, while documenting transient rises in prolactin, ACTH and cortisol alongside growth hormone (Massoud et al., 1996; Arvat et al., 1997). Studies in which hexarelin was given during sleep reported increases in growth hormone and prolactin across the night together with ACTH and cortisol increases in the first half of the night, and a reduction in slow-wave sleep, which indicates that effects on sleep architecture are measurable.

Beyond that, the recognised concerns are mechanistic and class-based. They include pituitary desensitization with repeated exposure, documented directly for hexarelin; activation of the adrenal axis and of prolactin secretion with bolus administration; and the metabolic consequences that attach to any sustained increase in growth hormone, notably reduced insulin sensitivity and higher glucose, along with fluid retention, joint discomfort and the nerve compression symptoms familiar from growth hormone excess. Ghrelin receptor agonists as a class also stimulate appetite, which is a desired effect in cachexia research and an unwanted one elsewhere.

Several specific unknowns deserve naming. No study has characterised the long-term consequences of chronic CD36 activation in humans. No study has established whether stimulating the growth hormone axis is safe in people with undiagnosed neoplasia, a theoretical concern for the entire growth hormone and IGF-1 field. No study has examined interactions with prescription medicines, pregnancy or lactation, or paediatric use outside the short diagnostic protocols of the 1990s. Non-sterile or mislabelled material adds injection-site infection and contaminant exposure to this list.

Consult a healthcare professional before acting on anything in this guide. Hexarelin is a research peptide, not a treatment, and its risk profile is characterised by what has not been studied at least as much as by what has.